CLINICAL STUDY

FOXP3, RORγt and IL-10 cytokine profile in chronic heart failure

Gorzin F1, Amirzargar AA1, Mahmoudi MJ2, Rahnmoon Z3, Najmi Varzaneh F4,5, Hedayat M6,7, Sadati S1, Eskandari V1, Rahmati Z1, Rezaei N1,8,9

Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. rezaei_nima@tums.ac.ir

ABSTRACT

BACKGROUND: Distinct subsets of T cells play crucial regulatory roles in inflammatory processes of chronic heart failure (CHF). Retinoic acid receptor-related orphan receptor-γt (RORγt) and Forkhead box P3 (FOXP3) have been defined as the “master regulators” of Th17 cells and Treg cells, respectively. At the same time, anti-inflammatory cytokines such as IL-10 may neutralize inflammation in CHF. The current study was designed to compare FOXp3, RORγt and IL-10 protein expression in the blood and IL-10 in supernatant PBMCs in CHF patients versus normal subjects.

PATIENTS AND METHODS: Our study population consisted of 42 patients with CHF in four different function classes and 42 healthy subjects who served as controls. RNA extraction and cDNA synthesis was performed and mRNA expression for genes FOXP3, RORγt, IL-10 was determined by RT-PCR. The amount of IL-10 protein in supernatant of PBMCs was measured by ELISA technique.

RESULTS: There was no significant difference in FOXp3, RORγt, IL-10 protein expression and supernatant PBMCs IL-10 in CHF patients as compared to control. The level of Foxp3 was significantly lower in CHF patients with ischemic vs non-ischemic cause (p = 0.04).

DISCUSSION: Although inflammation plays a central role in the pathophysiology of CHF, the roles of FOXp3, RORγt, and IL-10 remain to be determined (Tab. 3, Ref. 33). Text in PDF www.elis.sk.

KEY WORDS: CHF, inflammation, FOXp3, RORγt, IL-10.

Introduction

Heart failure (HF) is one of the most common cardiovascular diseases, which represents a major public health burden (1, 2). Congestive heart failure (CHF), as a multifaceted clinical syndrome, is no longer merely a pump failure of the heart but a multisystem disease which affects humoral, neuroendocrine, re-

1Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 2Department of Cardiology, Amir Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran, 3Cardiac Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 4The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 5Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Baltimore, MD, USA, 6Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, 7Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Boston, MA, USA, 8Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran, and 9Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Sheffield, UK

Address for correspondence: N. Rezaei, MD, PhD, Children’s Medical Center Hospital, Dr. Gharib St, Keshavarz Blvd, Tehran, Iran. Phone: +9821.6692.9234, Fax: +9821.6692.9235

Acknowledgment: This study was supported by a grant from Tehran University of Medical Sciences (Grant number: 94-01-30-27572).
IL-6 cytokines-mediated signaling, upregulate the transcription stimulated with Ags upon activation of TCR and both TGFβ and feedback mechanism, which proposes the role of anti-inflammatory cytokines in CHF (12, 13).

In general, cytokines are interwoven and regulated through a feedback mechanism, which proposes the role of anti-inflammatory cytokines in CHF (12, 13).

Interleukin 10 (IL-10), an important negative regulator of pro-inflammatory cytokines, has potent suppressor properties in macrophages, T-cells and B cells (14). IL-10 has been shown to inherit an important role in the cytokine network and act as a downregulator of cell-mediated immune reactions in CHF patients (15, 16).

In the present study, we sought to evaluate the expression of genes including FOXP3, RORγt, IL-10 and measurement of IL-10 in peripheral blood mononuclear cell (PBMC) culture in CHF patients compared with healthy control subjects.

Materials and methods

Study population

Our study population consisted of 42 patients with CHF and 42 healthy subjects (individuals without coronary artery disease or heart failure) who served as controls. CHF patients were classified as ischemic heart failure (IHF) and non-ischemic heart failure (NIHF) based on their history of myocardial infarction or significant coronary artery stenosis. The characteristics of the study subjects are summarized in Table 1. Patients in the CHF group were enrolled during hospital admission for decompensated heart failure. All subjects underwent a physical examination and answered a standardized questionnaire to assess their medical history, current illnesses, and any medication they were taking. The diagnosis of CHF was based on clinical history, physical examination, electrocardiography, echocardiography and chest X-ray.

All patients were stable during the last month of the study without any change in medication. Exclusion criteria included all conditions that might influence the immune system, such as a recent or current infection, autoimmune disorder, allergic disease, malignant disease, advanced liver disease, renal failure, malnutrition and steroid therapy (within 3 months). Informed consent was obtained from each patient. CHF patients were classified into 4 groups according to New York Heart Association Class I to IV (17). The study was approved by the Ethical Committee of Tehran University Heart Center Hospital.

Hematologic analysis

Blood samples were obtained from all the subjects in recumbent position with a 21-gauge needle for clean venipuncture of an antecubital vein. Peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll density gradient for analysis of real time-polymerase chain reaction (RT-PCR), and cell culture was obtained after centrifugation and stored at -80°C. Foxp3, RORγt, and IL-10 expressions were measured by RT-PCR. Total RNA was extracted with phenyl chloroformate extraction (cinaclone) according to the manufacturer’s instructions. The cDNA was synthesized using random hexamer primers and RNase H-reverse transcriptase (Cinaclone). TaqMan primers and probes for human RORγt, Foxp3 and IL-10 were purchased from ABI Company; all reactions were performed using the Prism 23. For each sample, the mRNA expression level was normalized to the level of actin housekeeping genes.

For cell culture, freshly isolated PBMCs were stimulated with PHA (15 μg/ml) at the density of 2 * 106/ml in complete RPMI1640 with 10 % heat-inactivated fetal calf serum (Gibco BRL, USA) for 48 hours. Then the supernatant was collected and stored at –80 °C for the detection of IL-10 by ELISA. In each group, some samples have been excluded due to technical errors.

Statistical analysis

The data were analyzed by non-parametric methods to avoid assumptions about the distribution of the measured variables. For comparisons of groups, independent T test and ANOVA were used. All values are reported as mean ± SD. Analyses were performed using the SPSS 19 statistical software package program and p values of 0.05 or less were considered significant.

Results

Foxp3 expression in CHF patients

The mean level of Foxp3 expression were lower in the CHF patients (1.78 ± 2.05) than in the control group (1.67 ± 2.28), however the difference was not significant (p > 0.5) (Tab. 2).

The mean level of Foxp3 in CHF patients with ischemic etiology was 1.20 ± 1.32; whereas the mean level of Foxp3 in CHF patients with non-ischemic etiology was 3.15 ± 2.79; the difference, however, is not significant (p > 0.5) (Tab. 3).

The mean level of Foxp3 in CHF patients with function classes I, II, III and IV were 1.81 ± 1.64, 1.25 ± 1.28, 1.61 ± 2.18, and 2.31 ± 2.57, respectively. However, the difference between groups was not significant (p > 0.05) (Tab. 3).

RORγt expression in CHF patients

The mean level of RORγt expression was 1.61 ± 2.13 in CHF patients and 1.62 ± 1.98 in the control group. The difference between
Tab. 3. Comparison of Foxp3, ROR, IL-10 and IL-10 Pr in PBMC in CHF ischemic/non-ischemic patients and different function classes.

<table>
<thead>
<tr>
<th>Function Class</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHF</td>
<td>1.81±1.64</td>
<td>1.25±1.28</td>
<td>1.61±2.18</td>
<td>2.31±2.57</td>
</tr>
<tr>
<td></td>
<td>(n=4)</td>
<td>(n=10)</td>
<td>(n=10)</td>
<td>(n=13)</td>
</tr>
<tr>
<td>NIHF</td>
<td>1.20±1.32</td>
<td>0.66±0.77</td>
<td>0.95±2.14</td>
<td>2.04±2.62</td>
</tr>
<tr>
<td></td>
<td>(n=21)</td>
<td>(n=7)</td>
<td>(n=7)</td>
<td>(n=9)</td>
</tr>
<tr>
<td>ROR Level</td>
<td>1.16±1.66</td>
<td>1.63±1.97</td>
<td>1.75±1.71</td>
<td>1.43±1.32</td>
</tr>
<tr>
<td></td>
<td>(n=26)</td>
<td>(n=11)</td>
<td>(n=21)</td>
<td>(n=26)</td>
</tr>
<tr>
<td>IL-10 Level</td>
<td>0.69±0.72</td>
<td>2.96±2.89</td>
<td>1.38±2.02</td>
<td>1.25±2.02</td>
</tr>
<tr>
<td></td>
<td>(n=7)</td>
<td>(n=7)</td>
<td>(n=6)</td>
<td>(n=11)</td>
</tr>
<tr>
<td>IL10 Pr in PBMC</td>
<td>419.4±247.7</td>
<td>344.6±289.29</td>
<td>229.2±193.4</td>
<td>314.2±250.2</td>
</tr>
<tr>
<td></td>
<td>(n=25)</td>
<td>(n=9)</td>
<td>(n=6)</td>
<td>(n=10)</td>
</tr>
</tbody>
</table>

*Pr = protein

Discussion

Inflammation plays a significant contributory role in the pathogenesis of chronic heart failure (CHF). Several cell types and cytokines are involved in orchestrating this complex disease. Numerous studies have shown that T cells are involved in cardiac remodeling, and significantly alter the cardiac pathophysiology. Two distinct subsets of T helper (CD4), Treg and Th17 cells have crucial regulatory roles in cardiac function. Tregs have been identified as suppressors of diverse immune responses and inflammation, whereas Th17 promote inflammation by IL-17 production. Based on the cytokine-regulated balance of these two “master regulators”, Foxp3 and RORγt, Treg and Th17 would be differentiated, respectively.

A reduced number of circulating Treg with compromised function and less Foxp3 expression in PBMC in CHF patients have been previously reported (18). Moreover, it has been shown that Treg deficiency correlates with the severity of CHF and is reduced in both IHF and NIHF, which seemed to be independent of etiology (18).

The results of this study could not confirm any significant difference for Foxp3 between CHF and control groups. The level of Foxp3 did not show any correlation with CHF severity, but it appeared to be correlated with the cause of CHF as the level of Foxp3 was significantly lower in IHF vs NIHF patients.

Several previous studies have demonstrated the dysregulation of Foxp3 expression in numerous inflammatory diseases. A reduction in disease severity in models of Diabetes Mellitus, Multiple Sclerosis, asthma and inflammatory Bowel Disease by Foxp3 administration has been reported too (19, 20).

Since the balance between Foxp3 and RORγt has been demonstrated previously, we compared RORγt as well. Our result did not find any significant difference for RORγt between CHF patients and the normal group. In addition, there was neither significant correlation between RORγt level and CHF etiology, nor with CHF severity. The role of RORγt as potential therapeutic target for controlling inflammation in autoimmune diseases has been discussed by Huang et al (21).

In this regard, Hu et al identified the cardiac glycoside digoxin inhibit RORγt transcriptional activity and attenuate inflammatory lymphocyte function and autoimmune disease (22).

Targeting RORγt to therapeutically suppress inflammatory T cell function in numerous autoimmune disorders including ar-
thritis rheumatoid, psoriasis, autoimmune hepatitis and spondyloarthropathy has been reported previously (23-26). The role of Th17 and Treg in acute coronary syndrome (ACS) and myocardial infarction (MI) has been reported too. In this regard Cheng et al have showed a significant increase in peripheral Th17 number, Th17 related cytokines and RORγt levels and a decrease in Treg number and Foxp3 levels in ACS patients (27). In addition, Barry et al revealed enhanced expression of IL-17 T cell, IL17 cytokines and RORγt following ischemic reperfusion injury in MI models of rats (28).

Studies regarding CHF are sparse and lead to controversial findings (29, 30).

However, Li et al have stated a promising therapeutic approach by harmonizing the Th17/Treg balance in patients with CHF (29). The significant difference in circulating Th17, IL17 and RORγt between CHF patients and normal individuals was not confirmed by another study (30).

Since cytokines communicate between each other in a network, the role of anti-inflammatory cytokines is worth noting in inflammatory diseases. IL-10 is a potent anti-inflammatory cytokine which is known to suppress the synthesis of pro-inflammatory cytokines (31).

A previous study in mice models after MI induction and treatment with IL-10 demonstrated the suppressive effect of IL-10 which leads to left ventricular improvement, reduced infarct size, and attenuated infarct wall thinning (32).

Higher level of IL-10 in CHF patients and its correlation with CHF severity has been reported in previous studies (15, 33) which proposed IL-10 as an important inherent component of the cytokine network of CHF.

In the current study, the mean level of IL-10 expression was lower in CHF patients than in control group; the difference, however, was not significant (p > 0.5).

In addition, our data could not confirm any correlation between IL-10 level and CHF severity or CHF etiology which may be due to the small sample size in each group of patients.

In summary, this study shows a significant lower level of Foxp3 in IHF vs NIH. However, we could not confirm any significant changes in RORγt and IL-10 in CHF patient’s vs normal subjects. The limitation of the current study was the small size of samples which could have contributed to the failure to reach the statistical significance. Therefore, further research with a larger sample size needs to be conducted to identify more precisely the most important factors in the immunopathogenesis of chronic HF in the pursue of developing more specific immunomodulating agents for this disorder.

References


